Semaglutide After 60: What Changes With Age
We built this practice around adults over 45, so "after 60" is not a corner case for us. It is a large part of who we see. But 60 is not 45, and 70 is not 60, and the honest answer to "is semaglutide right for me at my age" has moved in the last eighteen months because the data has.
This page covers what the trials show in people over 65, what they do not, and the three things that change in the plan when the patient is older. The main semaglutide page has the general picture.
The 65+ data, finally
For most of semaglutide's history the answer to "does it work in older people" was an inference. The STEP trials included older adults, but not in numbers that let anyone say much about them specifically.
That changed in May 2026, when a pooled analysis of six STEP trials was presented at the European Congress on Obesity. It gathered every participant aged 65 and over — 358 people, mean age 69, nine in ten of them between 65 and 74, without diabetes — and looked at them on their own.
Over roughly 68 weeks, participants on semaglutide lost 15.4% of their body weight against 5.1% on placebo. Two in three lost at least a tenth of their body weight. Nearly half lost 15% or more. Waist circumference fell by 14 cm.
Those figures are essentially the same as the results in younger adults. Age, on this evidence, does not blunt the drug.
What the same analysis says about safety
The safety read is reassuring, with one number worth looking at directly.
Serious adverse events were more common on semaglutide — 19.0% versus 12.7% on placebo. That gap is larger than in the all-ages trials, and it is the kind of figure that gets quoted without context. In context: the trials ran for well over a year, the population was older, and the category is dominated by hospitalizations of any cause. It is a reason for closer follow-up in this age group, not a reason to rule the drug out. Fracture and hypoglycemia were each under 1% in both groups.
Constipation and dizziness were more common on semaglutide. Both matter more at 70 than at 50 — constipation because of what it does to comfort and adherence, dizziness because of what a fall costs.
The three things that change the plan
1. Muscle
The concern most often raised about GLP-1s in older adults is lean mass, and it is a legitimate one. Across the GLP-1 trials that measured body composition, a substantial share of the weight lost — figures up to 40% are cited in the review literature — was lean tissue rather than fat. That proportion is not unique to these drugs; it is what rapid weight loss by any means tends to do. The difference is that an older adult starts with less muscle and rebuilds it more slowly.
Sarcopenia already affects roughly one adult in three over 60. Losing muscle from that baseline is a different proposition from losing it at 45, and the consequences — strength, balance, independence — are the ones that actually decide how the next decade goes.
This is why we do not prescribe semaglutide in isolation at any age, and why after 60 the two non-drug parts of the plan stop being optional: resistance training and adequate protein. A dietitian can set the protein figure for you; we do not publish targets because they are individual. We do measure body composition at baseline and on a schedule, so that "losing weight" and "losing the right weight" are two different numbers on your chart, not one.
2. Bone
Weight loss unloads the skeleton, and there is a signal in the 2026 literature of an osteoporosis association with GLP-1 use that is still being characterized. In a woman past menopause who is not on estrogen, or in anyone with a prior fracture, that is enough to justify a baseline DEXA before starting rather than after. The 65+ pooled analysis found fracture rates under 1% in both arms, which is reassuring but is not the same as a long-term answer.
3. The medication list
At 45 the average patient is on nothing. At 68 the average patient is on several things, and two of them matter here. Any medication that lowers blood sugar on its own — a sulfonylurea or insulin, in someone with diabetes — raises hypoglycemia risk alongside a GLP-1. And anything whose absorption depends on gastric timing can behave differently when gastric emptying slows. Neither is a contraindication; both are a reason the medication list gets read properly before the first prescription, not after the first problem.
Hydration is the unglamorous fourth item. Reduced appetite reduces fluid intake as well as food, and dehydration in an older adult on a blood-pressure medication is a fall waiting to happen.
Who this is not for
The general exclusions on the main page apply. Beyond them, we are more cautious after 60 with anyone who has already lost muscle or function — an unintended weight loss in the previous year, a history of falls, difficulty rising from a chair. In that person the risk of accelerating a decline can outweigh the metabolic benefit, and the honest recommendation is sometimes to build first and treat later.
We also do not use a BMI cut-off as a hard gate at any age; the reasoning is on the main page. In older adults, the case for looking past BMI to composition is stronger still.
Frequently asked questions
The 2026 pooled analysis of adults 65 and over found weight loss comparable to younger adults, with serious adverse events more frequent than placebo (19% vs 12.7%) and fracture and hypoglycemia each under 1%. It is a drug for closer monitoring in this age group, not a drug to avoid.
Not in the label. The trial data is thin above 75, and the assessment becomes more individual with age — function, muscle and medication list matter more than the birth year.
Some lean mass is lost with any significant weight loss. After 60 it matters more and comes back slower, which is why resistance training, protein and body-composition monitoring are part of the plan, not suggestions.
Since July 2026 the Medicare GLP-1 Bridge program covers Wegovy for obesity under specific criteria, separately from standard Part D. See Medicare and GLP-1s.
Yes, in a manageable way. Weight loss often lowers blood pressure, which can mean an existing medication needs adjusting by whoever prescribes it. Tell us everything you take.
If you are postmenopausal and not on estrogen, have had a fracture, or have any other osteoporosis risk factor, we would rather have a DEXA on file before you start.
Where this fits in your plan
Begin with a baseline panel and, after 60, a body-composition measurement. The main Semaglutide Injection page covers how the medication is used here; the Tirzepatide page covers the alternative.
We measure first. Then we act.
References
- Busetto L et al. Efficacy and safety of once-weekly semaglutide in adults aged ≥65 years: pooled post-hoc analysis of STEP 1, 3, 4, 5, 8 and 9. European Congress on Obesity, May 2026.
- Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). NEJM 2021;384:989–1002.
- Lincoff AM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). NEJM 2023;389:2221–2232.
- Review literature on lean-mass loss with GLP-1 receptor agonists, 2025–2026 (e.g. British Journal of Pharmacology, January 2026).
- Cruz-Jentoft AJ et al. Sarcopenia: revised European consensus on definition and diagnosis. Age and Aging 2019.
- 2026 GLP-1 osteoporosis association signal.
How we write and review our content
ACT 2 Health provides clinician-led care. Treatments are available only to eligible patients following clinical evaluation and within applicable regulations. This content is educational and is not medical advice. Individual results vary.
All medical decisions are made solely by licensed healthcare professionals. Medications are prescribed only when medically necessary. GLP-1 medications are not suitable for everyone. Results may vary.
Compounded medication. Prepared by a licensed compounding pharmacy under a prescription written for you. Compounded medications are not FDA-approved, are not reviewed by the FDA for safety or effectiveness, and are not equivalent to or interchangeable with any branded product. Prescribed only when a licensed provider determines it is medically appropriate.
Care is delivered via telemedicine by healthcare professionals licensed in the state where the patient is located. Services are available only in states where our providers are licensed.